This inventor holds 1 USPTO granted patent and 7 published patent applications, plus 1 CIPO patent. Top assignee: Johns Hopkins University. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Innovations of Nicholas J Boylan in Corneal Allograft Rejection Prevention
Introduction
Nicholas J Boylan is an accomplished inventor based in East Boston, MD (US). He has made significant contributions to the field of biomedical engineering, particularly in the area of corneal transplantation. His innovative work focuses on developing advanced drug delivery systems to enhance the success of corneal grafts.
Latest Patents
Nicholas J Boylan holds a patent for "Glucocorticoid-loaded nanoparticles for prevention of corneal allograft rejection and neovascularization." This invention involves particles that encapsulate a glucocorticoid, such as dexamethasone sodium phosphate (DSP), within a biodegradable matrix like poly(lactic-coglycolic acid) (PLGA). These nanoparticles are densely coated with hydrophilic polymers, such as PEG or PLURONIC® F127, allowing for the sustained release of DSP for up to 7 days in vitro. This innovative approach aims to prevent corneal graft rejection and neovascularization, significantly improving patient outcomes.
Career Highlights
Nicholas J Boylan is affiliated with Johns Hopkins University, where he continues to advance his research in drug delivery systems. His work has garnered attention for its potential to revolutionize the treatment of corneal transplant patients. With a focus on practical applications, Boylan's research is paving the way for new therapeutic strategies in ophthalmology.
Collaborations
Throughout his career, Nicholas has collaborated with esteemed colleagues, including Qing Pan and Bing Wang. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in the field.
Conclusion
Nicholas J Boylan's contributions to the field of corneal transplantation through his innovative patent demonstrate his commitment to improving patient care. His work exemplifies the intersection of science and technology, showcasing the potential of targeted drug delivery systems in medical applications.